MSCL.TO Satellos Bioscience Inc.

Healthcare Biotechnology Toronto Exchange
10.12 CAD
Close of Nov 7, 2026
7.56 18.98
Market cap
CAD 215M
P/E
-
P/B
2.56x
ROE
-72.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is MSCL.TO undervalued?

Graham number

The Graham number of Satellos Bioscience Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Satellos Bioscience Inc. fundamental analysis

No fundamental analysis for Satellos Bioscience Inc. yet.

Satellos Bioscience Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Satellos Bioscience Inc.

Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247, an oral, small molecule drug candidate for the treatment of Duchenne muscular dystrophy disease.…

Full company profile